Our Blog - ELIAS Animal Health: Insights on Cancer Immunotherapy

USDA Agrees Clinical Trial Data for the ELIAS Cancer Immunotherapy (ECI®) Demonstrates Reasonable Expectation of Efficacy for the Treatment of Bone Cancer in Dogs

First-in-class adoptive cell therapy for treatment of osteosarcoma, a deadly form of bone cancer in dogs OLATHE, Kan., Jan. 17, [...]

January 17th, 2024|

After successfully concluding a clinical trial for canine osteosarcoma, ELIAS Animal Health is focused on continuing to push forward in [...]

November 2nd, 2023|

Pets bring us immense joy and companionship, making them cherished members of our families. However, just like humans, they too [...]

October 31st, 2023|

ELIAS Animal Health previously announced it has in-licensed an oncolytic vaccinia virus treatment for pet animals from Genelux Corporation. The [...]

October 13th, 2023|

Our mission at ELIAS Animal Health is to improve cancer treatment outcomes in veterinary patients through the advancement of innovative [...]

April 26th, 2023|

January is One Health Awareness Month, which recognizes and promotes the "interconnectedness of the health of people, animals, and the [...]

January 10th, 2023|

Artist interpretation: Cytotoxic T cells (blue) attack a cancer cell (orange). The immune system hosts an army of [...]

December 19th, 2022|